BresMed, and international HEOR consultancy, developed a white paper exploring eight key challenges that manufacturers face when demonstrating the value of rare disease products to decision-makers. They describe their framework for proactively overcoming these challenges so that manufacturers can achieve earlier access to market, at a price that reflects product value. A lack of head-to-head trial data can be a key challenge to demonstrating the value of drugs for rare diseases. Download the white paper that identifies 8 common challenges and a framework for overcoming them, designed by BresMed’s rare disease experts.
Download White Paper here.